A Clinical Research Study Testing Ropinirole Treatment for Restless Legs Syndrome
Public ClinicalTrials.gov record NCT00363857. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A 12-Week, Double-Blind, Placebo Controlled, Parallel Group Study to Assess the Efficacy and Safety of Ropinirole in Patients Suffering From Restless Legs Syndrome (RLS)
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
A 14-Week clinical research study to compare the effectiveness and safety of ropinirole and placebo (an inactive sugar pill) in the treatment of patients with Restless Legs Syndrome (RLS) in the United States.
Study identification
- NCT ID
- NCT00363857
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 3
- Enrollment
- 360 participants
Conditions and interventions
Eligibility (public fields only)
- Age range
- 18 Years to 79 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Aug 2003 (Type not available)
- Primary completion
- May 2004 (Actual)
- Completion
- May 2004 (Actual)
- Last update posted
- Oct 17, 2016
2003 – 2004
United States locations
- U.S. sites
- 49
- U.S. states
- 25
- U.S. cities
- 47
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| GSK Investigational Site | Alabaster | Alabama | 35007 | — |
| GSK Investigational Site | Birmingham | Alabama | 35294 | — |
| GSK Investigational Site | Jasper | Alabama | 35501 | — |
| GSK Investigational Site | Tuscaloosa | Alabama | 35406 | — |
| GSK Investigational Site | Phoenix | Arizona | 85032 | — |
| GSK Investigational Site | Phoenix | Arizona | 85050 | — |
| GSK Investigational Site | Little Rock | Arkansas | 72205 | — |
| GSK Investigational Site | Berkeley | California | 94705 | — |
| GSK Investigational Site | La Jolla | California | 92037 | — |
| GSK Investigational Site | Northridge | California | 91325 | — |
| GSK Investigational Site | Oxnard | California | 93030 | — |
| GSK Investigational Site | Redondo Beach | California | 90277 | — |
| GSK Investigational Site | Santa Monica | California | 90404 | — |
| GSK Investigational Site | Stanford | California | 94305-5548 | — |
| GSK Investigational Site | Aurora | Colorado | 80012 | — |
| GSK Investigational Site | Danbury | Connecticut | 06810 | — |
| GSK Investigational Site | Boca Raton | Florida | 33486 | — |
| GSK Investigational Site | Largo | Florida | 33773 | — |
| GSK Investigational Site | Pembroke Pines | Florida | 33026 | — |
| GSK Investigational Site | St. Petersburg | Florida | 33701 | — |
| GSK Investigational Site | Tampa | Florida | 33606 | — |
| GSK Investigational Site | Tampa | Florida | 33609 | — |
| GSK Investigational Site | Atlanta | Georgia | 30329 | — |
| GSK Investigational Site | Augusta | Georgia | 30912 | — |
| GSK Investigational Site | Macon | Georgia | 31201 | — |
| GSK Investigational Site | Chicago | Illinois | 60611 | — |
| GSK Investigational Site | Elk Grove Village | Illinois | 60007 | — |
| GSK Investigational Site | Louisville | Kentucky | 40217 | — |
| GSK Investigational Site | Southfield | Michigan | 48034 | — |
| GSK Investigational Site | Henderson | Nevada | 89052 | — |
| GSK Investigational Site | Lebanon | New Hampshire | 03766 | — |
| GSK Investigational Site | Albuquerque | New Mexico | 87108 | — |
| GSK Investigational Site | Schenectady | New York | 12308 | — |
| GSK Investigational Site | Raleigh | North Carolina | 27607 | — |
| GSK Investigational Site | Columbus | Ohio | 43210-1296 | — |
| GSK Investigational Site | Concinnati | Ohio | 45219 | — |
| GSK Investigational Site | Dublin | Ohio | 43017 | — |
| GSK Investigational Site | Oklahoma City | Oklahoma | 73112 | — |
| GSK Investigational Site | Portland | Oregon | 97201 | — |
| GSK Investigational Site | Lafayette Hill | Pennsylvania | 19444 | — |
| GSK Investigational Site | Philadelphia | Pennsylvania | 19107 | — |
| GSK Investigational Site | Columbia | South Carolina | 29201 | — |
| GSK Investigational Site | Nashville | Tennessee | 37205 | — |
| GSK Investigational Site | Austin | Texas | 78756 | — |
| GSK Investigational Site | Dallas | Texas | 75231 | — |
| GSK Investigational Site | Plano | Texas | 75093 | — |
| GSK Investigational Site | Alexandria | Virginia | 22311 | — |
| GSK Investigational Site | Norfolk | Virginia | 23507 | — |
| GSK Investigational Site | Walla Walla | Washington | 99362 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT00363857, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Oct 17, 2016 · Synced Oct 19, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT00363857 live on ClinicalTrials.gov.